Top

Published in:

Open Access 01-12-2015 | Commentary

A shared mechanism of muscle wasting in cancer and Huntington’s disease

Authors: Michal Mielcarek, Mark Isalan

Published in: Clinical and Translational Medicine | Issue 1/2015

Abstract

Skeletal muscle loss and dysfunction in aging and chronic diseases is one of the major causes of mortality in patients, and is relevant for a wide variety of diseases such as neurodegeneration and cancer. Muscle loss is accompanied by changes in gene expression and metabolism that lead to contractile impairment and likely affect whole-body metabolism and function. The changes may be caused by inactivity, inflammation, age-related factors or unbalanced nutrition. Although links with skeletal muscle loss have been found in diseases with disparate aetiologies, for example both in Huntington’s disease (HD) and cancer cachexia, the outcome is a similar impairment and mortality. This short commentary aims to summarize recent achievements in the identification of common mechanisms leading to the skeletal muscle wasting syndrome seen in diseases as different as cancer and HD. The latter is the most common hereditary neurodegenerative disorder and muscle wasting is an important component of its pathology. In addition, possible therapeutic strategies for anti-cachectic treatment will be also discussed in the light of their translation into possible therapeutic approaches for HD.

Harper PS (1992) The epidemiology of Huntington’s disease. Hum Genet 89(4):365–376CrossRefPubMed

Zielonka D, Mielcarek M, Landwehrmeyer GB (2015) Update on Huntington’s disease: advances in care and emerging therapeutic options. Parkinsonism Relat Disord 21(3):169–178CrossRefPubMed

Gutekunst CA, Li SH, Yi H, Mulroy JS, Kuemmerle S, Jones R et al (1999) Nuclear and neuropil aggregates in Huntington’s disease: relationship to neuropathology. J Neurosci 19(7):2522–2534PubMed

Mielcarek M, Inuabasi L, Bondulich MK, Muller T, Osborne GF, Franklin SA et al (2014) Dysfunction of the CNS–heart axis in mouse models of Huntington’s disease. PLoS Genet 10(8):e1004550PubMedCentralCrossRefPubMed

Mielcarek M, Bondulich MK, Inuabasi L, Franklin SA, Muller T, Bates GP (2014) The Huntington’s disease-related cardiomyopathy prevents a hypertrophic response in the R6/2 mouse model. PLoS One 9(9):e108961PubMedCentralCrossRefPubMed

Zielonka D, Piotrowska I, Mielcarek M (2014) Cardiac dysfunction in Huntington’s disease. Exp Clin Cardiol 20:2547–2554

Zielonka D, Piotrowska I, Marcinkowski JT, Mielcarek M (2014) Skeletal muscle pathology in Huntington’s disease. Front Physiol 5:380PubMedCentralCrossRefPubMed

Huang S, Yang S, Guo J, Yan S, Gaertig MA, Li S et al (2015) Large polyglutamine repeats cause muscle degeneration in SCA17 mice. Cell Rep 13(1):196–208CrossRefPubMed

Boyle PA, Buchman AS, Wilson RS, Leurgans SE, Bennett DA (2009) Association of muscle strength with the risk of Alzheimer disease and the rate of cognitive decline in community-dwelling older persons. Arch Neurol 66(11):1339–1344PubMedCentralCrossRefPubMed

10.

Springer J, Schust S, Peske K, Tschirner A, Rex A, Engel O et al (2014) Catabolic signaling and muscle wasting after acute ischemic stroke in mice: indication for a stroke-specific sarcopenia. Stroke 45(12):3675–3683CrossRefPubMed

11.

Mielcarek M, Toczek M, Smeets CJ, Franklin SA, Bondulich MK, Jolinon N et al (2015) HDAC4–myogenin axis as an important marker of HD-related skeletal muscle atrophy. PLoS Genet 11(3):e1005021PubMedCentralCrossRefPubMed

12.

Aulino P, Berardi E, Cardillo VM, Rizzuto E, Perniconi B, Ramina C et al (2010) Molecular, cellular and physiological characterization of the cancer cachexia-inducing C26 colon carcinoma in mouse. BMC Cancer 10:363PubMedCentralCrossRefPubMed

13.

Murphy KT, Chee A, Trieu J, Naim T, Lynch GS (2012) Importance of functional and metabolic impairments in the characterization of the C-26 murine model of cancer cachexia. Dis Model Mech 5(4):533–545PubMedCentralCrossRefPubMed

14.

Mochel F, Haller RG (2011) Energy deficit in Huntington disease: why it matters. J Clin Invest 121(2):493–499PubMedCentralCrossRefPubMed

15.

Magnusson-Lind A, Davidsson M, Silajdzic E, Hansen C, McCourt AC, Tabrizi SJ et al (2014) Skeletal muscle atrophy in R6/2 mice—altered circulating skeletal muscle markers and gene expression profile changes. J Huntingtons Dis 3(1):13–24PubMed

16.

Antunes D, Padrao AI, Maciel E, Santinha D, Oliveira P, Vitorino R et al (2014) Molecular insights into mitochondrial dysfunction in cancer-related muscle wasting. Biochim Biophys Acta 1841(6):896–905CrossRefPubMed

17.

Constantinou C, Fontes de Oliveira CC, Mintzopoulos D, Busquets S, He J, Kesarwani M et al (2011) Nuclear magnetic resonance in conjunction with functional genomics suggests mitochondrial dysfunction in a murine model of cancer cachexia. Int J Mol Med 27(1):15–24PubMedCentralPubMed

18.

Williams AH, Valdez G, Moresi V, Qi X, McAnally J, Elliott JL et al (2009) MicroRNA-206 delays ALS progression and promotes regeneration of neuromuscular synapses in mice. Science 326(5959):1549–1554PubMedCentralCrossRefPubMed

19.

Bruneteau G, Simonet T, Bauche S, Mandjee N, Malfatti E, Girard E et al (2013) Muscle histone deacetylase 4 upregulation in amyotrophic lateral sclerosis: potential role in reinnervation ability and disease progression. Brain 136(Pt 8):2359–2368CrossRefPubMed

20.

Bricceno KV, Sampognaro PJ, Van Meerbeke JP, Sumner CJ, Fischbeck KH, Burnett BG (2012) Histone deacetylase inhibition suppresses myogenin-dependent atrogene activation in spinal muscular atrophy mice. Hum Mol Genet 21(20):4448–4459PubMedCentralCrossRefPubMed

21.

Mielcarek M, Landles C, Weiss A, Bradaia A, Seredenina T, Inuabasi L et al (2013) HDAC4 reduction: a novel therapeutic strategy to target cytoplasmic huntingtin and ameliorate neurodegeneration. PLoS Biol 11(11):e1001717PubMedCentralCrossRefPubMed

22.

Mielcarek M, Benn CL, Franklin SA, Smith DL, Woodman B, Marks PA et al (2011) SAHA decreases HDAC 2 and 4 levels in vivo and improves molecular phenotypes in the R6/2 mouse model of Huntington’s disease. PLoS One 6(11):e27746PubMedCentralCrossRefPubMed

23.

Mielcarek M, Zielonka D, Carnemolla A, Marcinkowski JT, Guidez F (2015) HDAC4 as a potential therapeutic target in neurodegenerative diseases: a summary of recent achievements. Front Cell Neurosci 9:42PubMedCentralCrossRefPubMed

24.

Choi MC, Ryu S, Hao R, Wang B, Kapur M, Fan CM et al (2014) HDAC4 promotes Pax7-dependent satellite cell activation and muscle regeneration. EMBO Rep 15(11):1175–1183PubMedCentralCrossRefPubMed

25.

He WA, Berardi E, Cardillo VM, Acharyya S, Aulino P, Thomas-Ahner J et al (2013) NF-kappaB-mediated Pax7 dysregulation in the muscle microenvironment promotes cancer cachexia. J Clin Invest 123(11):4821–4835PubMedCentralCrossRefPubMed

26.

Inui A (1999) Cancer anorexia-cachexia syndrome: are neuropeptides the key? Cancer Res 59(18):4493–4501PubMed

27.

Braun TP, Zhu X, Szumowski M, Scott GD, Grossberg AJ, Levasseur PR et al (2011) Central nervous system inflammation induces muscle atrophy via activation of the hypothalamic-pituitary-adrenal axis. J Exp Med 208(12):2449–2463PubMedCentralCrossRefPubMed

28.

Chen JL, Walton KL, Winbanks CE, Murphy KT, Thomson RE, Makanji Y et al (2014) Elevated expression of activins promotes muscle wasting and cachexia. FASEB J 28(4):1711–1723CrossRefPubMed

29.

Lokireddy S, Wijesoma IW, Teng S, Bonala S, Gluckman PD, McFarlane C et al (2012) The ubiquitin ligase Mul1 induces mitophagy in skeletal muscle in response to muscle-wasting stimuli. Cell Metab 16(5):613–624CrossRefPubMed

30.

Zhou X, Wang JL, Lu J, Song Y, Kwak KS, Jiao Q et al (2010) Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell 142(4):531–543CrossRefPubMed

31.

Silva KA, Dong J, Dong Y, Dong Y, Schor N, Tweardy DJ et al (2015) Inhibition of Stat3 activation suppresses caspase-3 and the ubiquitin-proteasome system, leading to preservation of muscle mass in cancer cachexia. J Biol Chem 290(17):11177–11187CrossRefPubMed

32.

Kamei Y, Miura S, Suzuki M, Kai Y, Mizukami J, Taniguchi T et al (2004) Skeletal muscle FOXO1 (FKHR) transgenic mice have less skeletal muscle mass, down-regulated Type I (slow twitch/red muscle) fiber genes, and impaired glycemic control. J Biol Chem 279(39):41114–41123CrossRefPubMed

33.

Reed SA, Sandesara PB, Senf SM, Judge AR (2012) Inhibition of FoxO transcriptional activity prevents muscle fiber atrophy during cachexia and induces hypertrophy. FASEB J 26(3):987–1000PubMedCentralCrossRefPubMed

34.

Su J, Ekman C, Oskolkov N, Lahti L, Strom K, Brazma A et al (2015) A novel atlas of gene expression in human skeletal muscle reveals molecular changes associated with aging. Skelet Muscle 5:35PubMedCentralCrossRefPubMed

Title: A shared mechanism of muscle wasting in cancer and Huntington’s disease
Authors: Michal Mielcarek
Mark Isalan
Publication date: 01-12-2015
Publisher: Springer Berlin Heidelberg
Published in: Clinical and Translational Medicine / Issue 1/2015
Electronic ISSN: 2001-1326
DOI: https://doi.org/10.1186/s40169-015-0076-z

At a glance: The STEP trials

Springer Medicine

A shared mechanism of muscle wasting in cancer and Huntington’s disease

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2015

Study of phosphorylation events for cancer diagnoses and treatment

Vaccination in children with allergy to non active vaccine components

Incidence of kiaa1549-braf fusion gene in Egyptian pediatric low grade glioma

Towards pathway-centric cancer therapies via pharmacogenomic profiling analysis of ERK signalling pathway

Integrated EpCAM-independent subtraction enrichment and iFISH strategies to detect and classify disseminated and circulating tumors cells